Published in J Anal Toxicol on October 01, 1996
The pharmacological treatment of opioid addiction--a clinical perspective. Eur J Clin Pharmacol (2010) 1.30
The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol (2008) 1.21
Design and evaluation of matrix-based controlled release tablets of diclofenac sodium and chondroitin sulphate. AAPS PharmSciTech (2007) 1.12
The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction (2011) 1.06
Interpretation of oral fluid tests for drugs of abuse. Ann N Y Acad Sci (2007) 1.00
Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation. Psychopharmacology (Berl) (2008) 0.95
Update on the clinical use of buprenorphine: in opioid-related disorders. Can Fam Physician (2012) 0.91
Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women. Ther Drug Monit (2011) 0.89
Heroin detoxification with buprenorphine on an inpatient psychiatric unit. J Subst Abuse Treat (2002) 0.89
Morphine- and buprenorphine-induced analgesia and antihyperalgesia in a human inflammatory pain model: a double-blind, randomized, placebo-controlled, five-arm crossover study. J Pain Res (2013) 0.85
New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. Subst Abuse Rehabil (2015) 0.84
A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. J Pharmacol Exp Ther (2013) 0.81
Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users. Addict Biol (2014) 0.81
A Physiologically Based Pharmacokinetic Modeling Approach to Predict Buprenorphine Pharmacokinetics following Intravenous & Sublingual Administration. Br J Clin Pharmacol (2017) 0.79
Population pharmacokinetics of buprenorphine following a two-stage intravenous infusion in healthy volunteers. Eur J Clin Pharmacol (2007) 0.79
Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. Pharmacotherapy (2015) 0.79
(R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. Br J Clin Pharmacol (2010) 0.79
Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res (2015) 0.79
Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. Drug Alcohol Depend (2012) 0.78
Transdermal patches: history, development and pharmacology. Br J Pharmacol (2015) 0.78
Effects of mitragynine and 7-hydroxymitragynine (the alkaloids of Mitragyna speciosa Korth) on 4-methylumbelliferone glucuronidation in rat and human liver microsomes and recombinant human uridine 5'-diphospho-glucuronosyltransferase isoforms. Pharmacognosy Res (2015) 0.77
Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. Eur J Clin Pharmacol (2016) 0.76
Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy. Antimicrob Agents Chemother (2014) 0.75
High-sensitivity analysis of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.75
Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects. Pharmacol Res Perspect (2016) 0.75
[Transdermal buprenorphine for treatment of chronic tumor and non-tumor pain]. Wien Med Wochenschr (2003) 0.75
Buprenorphine and norbuprenorphine findings in hair during constant maintenance dosage. Int J Legal Med (2011) 0.75
Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature (1999) 23.62
Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. J Virol (1998) 7.41
Quantitative fluorescence resonance energy transfer measurements using fluorescence microscopy. Biophys J (1998) 6.27
Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics (1999) 6.23
Bax-independent inhibition of apoptosis by Bcl-XL. Nature (1996) 3.82
Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham-controlled, multicentre trial. Lancet (2011) 3.70
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
The autophagy effector Beclin 1: a novel BH3-only protein. Oncogene (2008) 2.94
Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci U S A (2001) 2.56
Beclin 1 contains a leucine-rich nuclear export signal that is required for its autophagy and tumor suppressor function. Cancer Res (2001) 2.51
Eating the enemy within: autophagy in infectious diseases. Cell Death Differ (2008) 2.17
Wisconsin Card Sorting Test performance in patients with focal frontal and posterior brain damage: effects of lesion location and test structure on separable cognitive processes. Neuropsychologia (2000) 2.03
Clinical pathology testing recommendations for nonclinical toxicity and safety studies. AACC-DACC/ASVCP Joint Task Force. Toxicol Pathol (1992) 1.94
Sweat testing for heroin, cocaine, and metabolites. J Anal Toxicol (1994) 1.86
Sindbis virus induces apoptosis through a caspase-dependent, CrmA-sensitive pathway. J Virol (1998) 1.71
Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics (2001) 1.66
Gas chromatographic procedures for determination of ethanol in postmortem blood using t-butanol and methyl ethyl ketone as internal standards. Forensic Sci Int (1996) 1.61
The role of antibody in recovery from alphavirus encephalitis. Immunol Rev (1997) 1.60
The effects of focal anterior and posterior brain lesions on verbal fluency. J Int Neuropsychol Soc (1998) 1.59
Autophagy in aging, disease and death: the true identity of a cell death impostor. Cell Death Differ (2009) 1.58
Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J Neurosci (1997) 1.54
Stroop performance in focal lesion patients: dissociation of processes and frontal lobe lesion location. Neuropsychologia (2001) 1.52
22q13.3 deletion syndrome: clinical and molecular analysis using array CGH. Am J Med Genet A (2010) 1.49
Long term intraparenchymal Ig secretion after acute viral encephalitis in mice. J Immunol (1992) 1.45
Anti-CD3/anti-CD28 monoclonal antibody-coated suture enhances the immune response of patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (1999) 1.40
Identification of genes involved in the host response to neurovirulent alphavirus infection. J Virol (2001) 1.39
Testing human hair for drugs of abuse. II. Identification of unique cocaine metabolites in hair of drug abusers and evaluation of decontamination procedures. J Anal Toxicol (1992) 1.39
Trimethobenzamide cross-reacts in immunoassays of amphetamine/methamphetamine. Clin Chem (1993) 1.39
The Trail Making Test: a study in focal lesion patients. Psychol Assess (2001) 1.38
Evaluation of six commercial amphetamine and methamphetamine immunoassays for cross-reactivity to phenylpropanolamine and ephedrine in urine. J Anal Toxicol (1992) 1.38
Intracerebral cytokine mRNA expression during fatal and nonfatal alphavirus encephalitis suggests a predominant type 2 T cell response. J Immunol (1994) 1.32
Sindbis virus vector system for functional analysis of apoptosis regulators. Methods Enzymol (2000) 1.22
Age-dependent susceptibility to fatal encephalitis: alphavirus infection of neurons. Arch Virol Suppl (1994) 1.21
Pharmacokinetics and pharmacodynamics of intranasal "snorted" heroin. J Anal Toxicol (1993) 1.21
Lesion Explorer: a comprehensive segmentation and parcellation package to obtain regional volumetrics for subcortical hyperintensities and intracranial tissue. Neuroimage (2010) 1.19
A robust method for extraction and automatic segmentation of brain images. Neuroimage (2002) 1.17
Simultaneous measurement of cocaine, cocaethylene, their metabolites, and "crack" pyrolysis products by gas chromatography-mass spectrometry. Clin Chem (1994) 1.16
Semiautomatic brain region extraction: a method of parcellating brain regions from structural magnetic resonance images. Neuroimage (2004) 1.14
Roles of immunoglobulin valency and the heavy-chain constant domain in antibody-mediated downregulation of Sindbis virus replication in persistently infected neurons. J Virol (1995) 1.10
Protein depletion and metabolic stress in elderly patients who have a fracture of the hip. J Bone Joint Surg Am (1992) 1.09
The transmembrane domains of Sindbis virus envelope glycoproteins induce cell death. J Virol (1998) 1.09
The immune response in viral encephalitis. Semin Immunol (1992) 1.07
Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation (1991) 1.07
Mefloquine distribution in postmortem cases. Forensic Sci Int (1994) 1.06
PACS clinical experience at Georgetown University. Comput Med Imaging Graph (1991) 1.06
Fatal methadone poisoning in children: Maryland 1992-1996. Subst Use Misuse (2000) 1.06
The effects of alphavirus infection on neurons. Ann Neurol (1994) 1.05
Immunochemical mechanisms of penicillin induced Coombs positivity and hemolytic anemia in man. Int Arch Allergy Appl Immunol (1967) 1.03
Gender differences in AIDS-relevant condom attitudes and condom use. AIDS Educ Prev (1993) 1.01
The acute period of recovery from traumatic brain injury: posttraumatic amnesia or posttraumatic confusional state? J Neurosurg (1999) 1.01
Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction (1998) 1.01
Resistance of interleukin-1beta-deficient mice to fatal Sindbis virus encephalitis. J Virol (1999) 1.00
Urine concentrations of ketamine and norketamine following illegal consumption. J Anal Toxicol (2001) 0.98
Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther (2011) 0.97
Dominant inhibitory Ras delays Sindbis virus-induced apoptosis in neuronal cells. J Virol (1996) 0.97
Ketoconazole for treatment of disseminated coccidioidomycosis. Ann Intern Med (1982) 0.96
Muscarinic versus nicotinic modulation of a visual task. a pet study using drug probes. Neuropsychopharmacology (2001) 0.95
Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol. J Anal Toxicol (1987) 0.93
Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog. Drug Metab Dispos (1978) 0.93
Immune deficiency following thermal trauma is associated with apoptotic cell death. J Clin Immunol (1995) 0.92
Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. J Anal Toxicol (2001) 0.90
Measurement of heroin and its metabolites by isotope-dilution electron-impact mass spectrometry. Clin Chem (1993) 0.90
Cocaine disposition in saliva following intravenous, intranasal, and smoked administration. J Anal Toxicol (1997) 0.90
Role of water reuse for enhancing integrated water management in Europe and Mediterranean countries. Water Sci Technol (2001) 0.89
Impaired event memory and recollection in a case of developmental amnesia. Neurocase (2011) 0.89
63Ni electron-capture gas chromatographic assay for buprenorphine and metabolites in human urine and feces. J Chromatogr (1985) 0.89
Iodine-induced hypothyroidism in full-term infants with congenital heart disease: more common than currently appreciated? J Clin Endocrinol Metab (2014) 0.88
The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion. Int Immunol (1997) 0.88
Breast cancer risk and fatty acids in the breast and abdominal adipose tissues. J Natl Cancer Inst (1994) 0.88
PACS clinical experience at Georgetown University. Int J Biomed Comput (1992) 0.88
Vitreous humor in the evaluation of postmortem blood ethanol concentrations. J Anal Toxicol (1991) 0.88
Vitamin B2 interference with TDx drugs-of-abuse assays. J Forensic Sci (1998) 0.88
Assessing methods for measuring compliance with a fat-controlled diet. Am J Public Health (1982) 0.88
Cocaine and metabolite excretion in saliva under stimulated and nonstimulated conditions. J Anal Toxicol (1993) 0.87
The detection of psilocin in human urine. J Forensic Sci (2001) 0.87
Structural interactions between actin, tropomyosin, caldesmon and calcium binding protein and the regulation of smooth muscle thin filaments. Acta Physiol Scand (1998) 0.87
Prescribing patterns in the New York City Medicaid program. Med Care (1974) 0.87
Accidental poisonings involving carbon monoxide, heating systems, and confined spaces. J Forensic Sci (1986) 0.87
Forensic drug testing for opiates. VI. Urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassays and gas chromatography-mass spectrometry. J Anal Toxicol (1995) 0.86
Cocaine metabolism and urinary excretion after different routes of administration. Ther Drug Monit (1998) 0.86
Diazepam and methadone blood levels following concurrent administration of diazepam and methadone. Drug Alcohol Depend (1986) 0.86
MDA-MDMA concentrations in urine specimens. J Anal Toxicol (1997) 0.86
Cardiac operations in patients with functioning renal allografts. J Thorac Cardiovasc Surg (1984) 0.86
Cocaine fatality: an unexplained blood concentration in a fatal overdose. Forensic Sci Int (1990) 0.86
Quality of well being in panic disorder: the assessment of psychiatric and general disability. J Affect Disord (2000) 0.85
An fMRI of sustained attention with endogenous and exogenous engagement. Brain Cogn (2004) 0.84
Effective dietary intervention in hypertensives: sodium restriction and weight reduction. J Am Diet Assoc (1985) 0.84
Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens Suppl (1994) 0.84
Fatality resulting from methylphenidate overdose. J Anal Toxicol (1986) 0.83
Tissue distribution of ketamine in a mixed drug fatality. J Forensic Sci (1997) 0.83
Cocaine contamination of United States paper currency. J Anal Toxicol (1997) 0.83
The occurrence of cocaine, heroin and metabolites in hair of drug abusers. Forensic Sci Int (1993) 0.83
Cavitary acetabular defects treated with morselized cancellous bone graft and cementless cups. Int Orthop (2006) 0.82
Simultaneous assay of buprenorphine and norbuprenorphine by negative chemical ionization tandem mass spectrometry. J Anal Toxicol (1997) 0.82
Cocaine disposition in meconium from newborns of cocaine-abusing mothers and urine of adult drug users. J Anal Toxicol (1996) 0.82
Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog. Drug Metab Dispos (1983) 0.82
In vivo adulteration: excess fluid ingestion causes false-negative marijuana and cocaine urine test results. J Anal Toxicol (1998) 0.82